PTC Therapeutics, Inc.
PTCT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $3,469 | $2,063 | $2,738 | $2,807 |
| - Cash | $780 | $594 | $280 | $190 |
| + Debt | $2,471 | $2,229 | $1,462 | $1,269 |
| Enterprise Value | $5,160 | $3,698 | $3,920 | $3,886 |
| Revenue | $807 | $938 | $699 | $539 |
| % Growth | -14% | 34.2% | 29.7% | – |
| Gross Profit | $749 | $872 | $654 | $506 |
| % Margin | 92.9% | 93% | 93.6% | 94% |
| EBITDA | -$120 | -$330 | -$368 | -$368 |
| % Margin | -14.9% | -35.2% | -52.6% | -68.4% |
| Net Income | -$363 | -$627 | -$559 | -$524 |
| % Margin | -45% | -66.8% | -80% | -97.3% |
| EPS Diluted | -4.73 | -8.37 | -7.79 | -7.43 |
| % Growth | 43.5% | -7.4% | -4.8% | – |
| Operating Cash Flow | -$108 | -$158 | -$357 | -$251 |
| Capital Expenditures | -$74 | -$121 | -$152 | -$85 |
| Free Cash Flow | -$182 | -$279 | -$509 | -$337 |